PharmaShots Weekly Snapshots (September 12 - 16, 2022)
Published: Sept 16, 2022 | Tags: Enzolytics, Abveris, Monoclonal Antibodies, Multiple Viral Infectious Diseases, Biotech
Published: Sept 16, 2022 | Tags: Agios, Pyrukynd, mitapivat, PK Deficiency, Regulatory, EMA, CHMP, Positive Opinion, Marketing Authorization
Published: Sept 16, 2022 | Tags: AstraZeneca, Sanofi, Beyfortus, nirsevimab, RSV Lower Respiratory Tract Disease , Regulatory, EMA, CHMP, Positive Opinion
Published: Sept 16, 2022 | Tags: Sanofi, Regeneron, Dupixent, dupilumab, Atopic Dermatitis, Clinical Trial, P-III Trial
Gilead’s Veklury (remdesivir) Receives WHO’s Recommendation for the Treatment of COVID-19
Published: Sept 16, 2022 | Tags: Gilead, Veklury, remdesivir, COVID-19, Regulatory, WHO, Recommendation
Published: Sept 16, 2022 | Tags: NeuroBo, Dong-A, DA-1241, DA-1726, nonalcoholic steatohepatitis, obesity, type 2 diabetes, Pharma
Published: Sept 15, 2022 | Tags: Ascletis Pharma, ASC22, envafolimab, Chidamide, HIV Infection, Clinical Trial
Published: Sept 15, 2022 | Tags: Pfizer, Pentavalent Meningococcal Vaccine, MenABCWY, Invasive Meningococcal Disease, Clinical Trial, P-III Trial
Published: Sept 15, 2022 | Tags: Qurient, MSD, Q901, Keytruda, pembrolizumab, Advanced Solid Tumors, Pharma
Published: Sept 15, 2022 | Tags: Mallinckrodt, Terlivaz, terlipressin, Hepatorenal Syndrome, Regulatory, US, FDA, Approval
Published: Sept 15, 2022 | Tags: Horizon, Krystexxa, pegloticase, Uncontrolled Gout, Clinical Trial, P-IV (MIRROR) Trial, Arthritis & Rheumatology
Neuron23 Collaborated with QIAGEN to Develop CDx for LRRK2 inhibitor to Treat Parkinson's Disease
Published: Sept 15, 2022 | Tags: Neuron23, QIAGEN, CDx, LRRK2 inhibitor, Parkinson's Disease, Pharma, US, FDA, PMA
Published: Sept 14, 2022 | Tags: Valeo Pharma, Veru, Sabizabulin, COVID-19, Canada, Commercial Services Agreement, Pharma
Published: Sept 14, 2022 | Tags: Coave, Institute of Neurodegenerative Diseases, Gene Therapy, Biotech, Neurodegenerative Disorders
Published: Sept 14, 2022 | Tags: MD Anderson, Radiopharm Theranostics, Joint Venture, Radiopharmaceuticals Therapies, Cancer, Pharma
Published: Sept 14, 2022 | Tags: Otsuka, Lundbeck, Aripiprazole, Schizophrenia, Bipolar I Disorder, Regulatory, US, FDA, NDA
Published: Sept 14, 2022 | Tags: Merck, Keytruda, pembrolizumab, Stage IIB or IIC Melanoma, Regulatory, Health Canada, Approval
Published: Sept 14, 2022 | Tags: Nacuity, Arctic. NPI-001, Hereditary Cystatin C Amyloid Angiopathy, Pharma, Iceland
Published: Sept 13, 2022 | Tags: METiS, Voronoi, Pan-RAF Inhibitor Program, Class II & III BRAF mutant cancer, CNS metastasis, Pharma, License Agreement
Published: Sept 13, 2022 | Tags: CStone, Sugemalimab, Extranodal Natural Killer, T-Cell Lymphoma, regulatory, NMPA, sNDA, Priority Review
Novo Nordisk Collaborated with Microsoft to Advance Drug Discovery and Development Using AI
Published: Sept 13, 2022 | Tags: Novo Nordisk, Microsoft, atherosclerosis, AI, Drug Discovery, Pharma
Published: Sept 13, 2022 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5 Bivalent Booster Vaccine, Regulatory, EMA, CHMP, Conditional Marketing Authorization
Published: Sept 13, 2022 | Tags: Astellas, Seagen, Merck, Padcev, enfortumab vedotin-ejfv, Advanced Urothelial Cancer, Clinical Trial, P-Ib/II EV-103/KEYNOTE-869, Cohort K Trial
AmerisourceBergen to Acquire PharmaLex for ~$1.30B
Published: Sept 13, 2022 | Tags: AmerisourceBergen, PharmaLex, Acquire, ~$1.30B, M&A
Published: Sept 12, 2022 | Tags: AstraZeneca, Imfinzi, durvalumab, Metastatic Non-Small Cell Lung Cancer, Clinical Trial, P-III POSEIDON Trial
Published: Sept 12, 2022 | Tags: Ra Medical Systems, Catheter Precision, VIVO, Amigo, Cardiac Arrhythmias, M&A, Merger Agreement
Cellusion Entered into an Exclusive License Agreement with Celregen for CLS001 in the Greater China
Published: Sept 12, 2022 | Tags: Cellusion, Celregen, CLS001, bullous keratopathy, Pharma, Greater China
Published: Sept 12, 2022 | Tags: BMS, Sotyktu, deucravacitinib, Plaque Psoriasis, Regulatory, US, FDA, Approval
Published: Sept 12, 2022 | Tags: Amgen, Lumakras, Lumykras, sotorasib, Non-Small Cell Lung Cancer, Clinical Trial, P-III, CodeBreaK 200 Trial
Published: Sept 12, 2022 | Tags: AstraZeneca, Merck, Lynparza, Olaparib, Advanced Ovarian Cancer, P-III, PAOLA-1, SOLO-1, Trial
Related Post: PharmaShots Weekly Snapshots (September 05 - 09, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.